相关实验视频
Updated: May 15, 2025

08:25
Identification of Circular RNAs using RNA Sequencing
Published on: November 14, 2019
12.1K
揭示药物基因组学对循环RNA的洞察:在癌症治疗中准确医学
Saud Alqahtani1, Taha Alqahtani1, Krishnaraju Venkatesan1
1Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 62521, Saudi Arabia.
Biomolecules
|April 30, 2025
概括
循环RNAs (circRNAs) 是药物基因组学的关键,为个性化癌症治疗提供稳定的生物标志物. 它们有助于克服药物耐药性,并改善精密瘤学的治疗结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 药物基因组学可以通过基因分析来实现个性化医疗.
- 循环RNAs (circRNAs) 是稳定的非编码RNAs,调节药物耐药性和癌症进展.
- circRNAs独特的结构使它们成为有前途的生物标志物和治疗点.
研究的目的:
- 审查circRNAs在癌症治疗药物基因组学中的作用.
- 分析circRNA对药物代谢,疗效和毒性的影响.
- 讨论circRNAs作为精密瘤学的生物标志物和治疗剂.
主要方法:
- 在药物基因组学中对circRNAs进行全面的文献综述.
- 在化疗,向治疗和免疫治疗中分析circRNA调节网络.
- 检查用于circRNA研究的实验和生物信息学工具.
- 基于circRNA的疗法和输送系统的审查.
主要成果:
- circRNAs显著调节化疗耐药性,向治疗反应和免疫治疗结果.
- 多omics集成和机器学习帮助circRNA生物标记物的发现.
- circRNAs显示出作为疫苗,药物输送载体和合成治疗药物的潜力.
- 标准化和验证对于circRNA生物标志物的临床翻译至关重要.
结论:
- 将circRNA分析整合到药物基因组学中,代表了个性化癌症治疗的范式转变.
- circRNAs有可能克服耐药性并提高治疗疗效.
- 在精密瘤学中,circRNAs对于优化患者的治疗结果至关重要.
相关概念视频
lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
Experimental RNAi
6.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.0K
MicroRNAs
2.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

